ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................*JBDM Ver 0.1.67 (18 Oct 2017) - 2999001/0The file contains technical information submitted after the application was filed and not included in this specification2747767CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120190717W173deBibliographieenBibliographyfrBibliographieEP12828679.6201208242014032420151015enenen201161528033 P20110826US201161528151 P20110827US2019071720192920140702201427201902202019082018082920190717201929A61K 31/497 20060101AFI20180802BHEP C07D 401/04 20060101ALI20180802BHEP C07D 403/04 20060101ALI20180802BHEP C07D 413/04 20060101ALI20180802BHEP C07D 241/42 20060101ALI20180802BHEP C07D 241/44 20060101ALI20180802BHEP A61P 35/00 20060101ALI20180802BHEP deBESTIMMTE CHEMISCHE STOFFE, ZUSAMMENSETZUNGEN UND VERFAHRENenCERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODSfrENTITÉS CHIMIQUES, COMPOSITIONS ET PROCÉDÉSWO-A1-2005/037285WO-A1-2009/012283WO-A2-2007/044729US-A1- 2010 286 142TSAI ET AL.: 'Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.' PNAS vol. 105, no. 8, 2008, pages 3041 - 3046, XP008146063BOLLAG ET AL.: 'Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.' NATURE vol. 467, no. 7315, 2010, pages 596 - 599, XP05514592620141215ZHU, Yong-liang41077 Pementel CourtFremont, CA 94539USQIAN, Xiangping114 Mira StreetFoster City, CA 94404USNeupharma, Inc.101819448SMK/FP72696731175 Chess Drive Suite 206Foster City, CA 94404USMewburn Ellis LLP101783151City Tower 40 Basinghall StreetLondon EC2V 5DEGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRUS201205239020120824enWO201303295120130307201310